D. Schmitz

发表

The human tumour suppressor LATS1 is activated by human MOB1 at the membrane.

B. Hemmings, A. Hergovich, D. Schmitz, 2006, Biochemical and biophysical research communications.

NDR Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes Apoptosis

Brian A. Hemmings, B. Hemmings, A. Hergovich, 2008, Current Biology.

Cancer Biology and the Principles of Targeted Cancer Drug Discovery

J. Mestan, D. Fabbro, D. Schmitz, 2017 .

Identification of CLEC12B, an Inhibitory Receptor on Myeloid Cells*

Sonja Textor, A. Cerwenka, D. Schmitz, 2007, Journal of Biological Chemistry.

Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer

Jason M. Johnson, J. Lee, F. Janku, 2022, The oncologist.

Ablation of the Kinase NDR1 Predisposes Mice to the Development of T Cell Lymphoma

B. Hemmings, S. Dirnhofer, D. Hynx, 2010, Science Signaling.

Generation of stable human cell lines with Tetracycline-inducible (Tet-on) shRNA or cDNA expression.

A. Hergovich, D. Schmitz, Marta Gomez-Martinez, 2013, Journal of visualized experiments : JoVE.

NDR kinases regulate essential cell processes from yeast to humans

B. Hemmings, A. Hergovich, D. Schmitz, 2006, Nature Reviews Molecular Cell Biology.

The MST1 and hMOB1 Tumor Suppressors Control Human Centrosome Duplication by Regulating NDR Kinase Phosphorylation

B. Hemmings, A. Hergovich, D. Schmitz, 2009, Current Biology.

Differential NDR/LATS Interactions with the Human MOB Family Reveal a Negative Role for Human MOB2 in the Regulation of Human NDR Kinases

B. Hemmings, A. Hergovich, D. Schmitz, 2010, Molecular and Cellular Biology.

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

F. Janku, M. Opyrchal, A. Wicki, 2019 .

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

S. Dimitrijević, A. Stathis, A. Wicki, 2016 .